SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-Q

QUARTERLY REPORT PURSUANT TO SECTION 17 OF THE SECURITIES
REGULATION CODE AND SRC RULE 17(2)(b) THEREUNDER

1. For the quarterly period ended

Mar 31, 2021

2. SEC Identification Number

148022

3. BIR Tax Identification No.

000-288-655-000

4. Exact name of issuer as specified in its charter

Euro-Med Laboratories Phil., Inc.

5. Province, country or other jurisdiction of incorporation or organization

Metro Manila

6. Industry Classification Code(SEC Use Only)

7. Address of principal office

PPL Building, United Nations Avenue corner San Marcelino St., Manila Postal Code 1007

8. Issuer's telephone number, including area code

00-63-2-85240091 to 98

9. Former name or former address, and former fiscal year, if changed since last report

N/A

10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
common shares	4,112,140,540

11. Are any or all of registrant's securities listed on a Stock Exchange?

Yes

No

If yes, state the name of such stock exchange and the classes of securities listed therein:

Philippine Stock Exchange, Inc.

12. Indicate by check mark whether the registrant:

(a) has filed all reports required to be filed by Section 17 of the SRC and SRC Rule 17 thereunder or Sections 11 of the RSA and RSA Rule 11(a)-1 thereunder, and Sections 26 and 141 of the Corporation Code of the Philippines, during the preceding twelve (12) months (or for such shorter period that the registrant was required to file such reports)

Yes

No

(b) has been subject to such filing requirements for the past ninety (90) days

Yes

No

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.

Euro-Med Laboratories Phil., Inc.EURO

PSE Disclosure Form 17-2 - Quarterly Report References: SRC Rule 17 and
Sections 17.2 and 17.8 of the Revised Disclosure Rules

For the period ended	Mar 31, 2021
Currency (indicate units, if applicable)	Php

Balance Sheet

	Period Ended	Fiscal Year Ended (Audited)
	Mar 31, 2021	Dec 31, 2020
Current Assets	4,143,407,936	4,312,026,063
Total Assets	9,884,280,625	10,071,636,206
Current Liabilities	3,616,147,113	3,833,431,833
Total Liabilities	4,406,526,809	4,623,811,529
Retained Earnings/(Deficit)	1,354,599,093	1,324,669,954
Stockholders' Equity	5,477,753,816	5,447,824,677
Stockholders' Equity - Parent	1,260,620,702	1,230,631,494
Book Value per Share	1.33	1.32

Income Statement

	Current Year (3 Months)	Previous Year (3 Months)	Current Year-To-Date	Previous Year-To-Date
Gross Revenue	330,379,203	419,454,139	330,379,203	419,454,139
Gross Expense	289,705,242	353,041,249	289,705,242	353,041,249
Non-Operating Income	712,871	1,512,572	712,871	1,512,572
Non-Operating Expense	58,519,334	47,422,512	58,519,334	47,422,512
Income/(Loss) Before Tax	40,673,961	66,412,890	40,673,961	66,412,890
Income Tax Expense	10,744,822	20,038,461	10,744,822	20,038,461
Net Income/(Loss) After Tax	29,929,139	46,374,429	29,929,139	46,374,429
Net Income Attributable to Parent Equity Holder	29,929,139	46,374,429	29,929,139	46,374,429
Earnings/(Loss) Per Share (Basic)	0.01	0.01	0.01	0.01
Earnings/(Loss) Per Share (Diluted)	0.01	0.01	0.01	0.01

	Current Year (Trailing 12 months)	Previous Year (Trailing 12 months)
Earnings/(Loss) Per Share (Basic)	0.01	0.01
Earnings/(Loss) Per Share (Diluted)	0.01	0.01

Other Relevant Information
None